News-Medical.Net October 17, 2024
Nagoya University

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial. However, the speed of vaccine production is limited because the mRNA used in it is partly chemically synthesized and partly synthesized using enzymes, a relatively slow process.

A team of researchers from Nagoya University in Japan has successfully developed an innovative synthesis technology capable of producing high purity, fully chemically synthesized mRNA, cutting out the slower enzyme reactions. This advancement establishes a foundation for more rapid reactions to viral outbreaks and emerging diseases, which will hopefully lead to mitigation of future infections at a preliminary stage. Their results were published in the journal Nucleic Acids...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article